News
-
-
COMMUNIQUÉ DE PRESSE
As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo
NanoViricides, Inc. receives approval for Phase II Clinical Trial of NV-387 Oral Gummies as Treatment for Bundibugyo Ebolavirus in DR Congo, addressing lack of effective Ebola treatments -
-
-
-
-
COMMUNIQUÉ DE PRESSE
Revolune Announces Commercial Availability of Multiplex Immunofluorescence Reagents
Revolune announces commercial availability of multiplex immunofluorescence reagents, appoints Adrian Arechiga as Chief Commercial Officer. Company simplifies spatial biology workflows with scalable solutions -
-
-
COMMUNIQUÉ DE PRESSE
NuRAN Wireless Files 40-F Registration Statement with SEC in Advance of U.S. Listing - A Major Step Toward Nasdaq
NuRAN Wireless announces transformative capital markets milestones to expand global access: SEC Form 40-F filing for Nasdaq listing & confidential filing of C$100M Shelf Prospectus with BCSC